Karel Domansky new Director of Hardware R&D at MIMETAS
The workforce of Mimetas has recently been strengthened by Karel Domansky, who is a true expert in the field of organ-on-a-chip products. We ask him a couple of questions, to give some insight into the views of the new Director of Hardware Research and Development.
What is your experience in the organ-on-a-chip field?
I have been working in the organ-on-a-chip field for 20 years, which spans nearly the entire existence of the field. I started the work with the liver chip at the Massachusetts Institute of Technology and then continued with other organ chips at the Wyss Institute for Biologically Inspired Engineering at Harvard University. After 17 years of academic and translational research, I started my organ chip consulting company and supported startups in the field, such as Nortis, Inc. and NanoSurface Biomedical, Inc., as well as institutions such as the Kidney Research Institute.
How do you see Mimetas transforming the organ-on-a-chip field in the upcoming years?
Mimetas is going to transform the organ chip field because its cell culture platform is 3D, perfused, and scalable with open well architecture. The 3D perfused aspect provides superior cell performance while the open well architecture and scalability allow Mimetas to take full advantage of automated liquid handling. Robotic liquid handling can cover a wide range of tasks including filling the chips with extracellular matrix, cell and tissue seeding, exchanging cell culture medium and collecting samples. I believe it is the rollout of Mimetas’ top-performing organ-on-a-chip models in higher throughput format combined with robotic liquid handling that is going to have an immense impact on the field.
What do you think you will contribute to the company?
I will strive to help to conceive, develop, and deliver the best organ-on-a-chip products to the market while tying the knot between 3D perfused models and automated liquid handling to amplify the impact.
Interviewed by Indi Joore